Untargeted metabolomics based on ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) analyses were performed to identify biomarkers associated with intracranial tumors in children undergoing high-dose methotrexate (HDMTX) chemotherapy, using untargeted metabolomics to enable early detection of delayed drug elimination. Based on multivariate statistical analysis and regression models, we identified differential metabolites in the serum and investigated different metabolic pathways. A total of 48 differential serum metabolites were identified. Metabolic pathway analysis showed that there were significant differences in patients in terms of sphingolipid and glycerophospholipid metabolism pathways between the two groups. Among these, 10 differential metabolites were selected as candidate biomarkers for further validation. The biomarkers identified in this study effectively distinguished between normal and delayed MTX elimination, providing a potential early-warning tool for delayed drug clearance.
Shi, Z.Y. et al. / J. Chin. Pharm. Sci. 2026, 35 (4), 329–339.
>
>